company background image
6600 logo

SciClone Pharmaceuticals (Holdings) SEHK:6600 Stock Report

Last Price

HK$18.60

Market Cap

HK$11.3b

7D

0.2%

1Y

69.4%

Updated

18 Jun, 2024

Data

Company Financials +

SciClone Pharmaceuticals (Holdings) Limited

SEHK:6600 Stock Report

Market Cap: HK$11.3b

6600 Stock Overview

A biopharmaceutical company, engages in the development and commercialization of pharmaceutical products in the therapeutic areas of oncology and severe infection in Mainland China and internationally.

6600 fundamental analysis
Snowflake Score
Valuation4/6
Future Growth3/6
Past Performance6/6
Financial Health6/6
Dividends0/6

SciClone Pharmaceuticals (Holdings) Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for SciClone Pharmaceuticals (Holdings)
Historical stock prices
Current Share PriceHK$18.60
52 Week HighHK$18.66
52 Week LowHK$8.75
Beta0.77
1 Month Change1.86%
3 Month Change15.96%
1 Year Change69.40%
3 Year Change30.25%
5 Year Changen/a
Change since IPO-1.06%

Recent News & Updates

SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 35% Price Boost Is Out Of Tune With Earnings

Apr 02
SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 35% Price Boost Is Out Of Tune With Earnings

Recent updates

SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 35% Price Boost Is Out Of Tune With Earnings

Apr 02
SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 35% Price Boost Is Out Of Tune With Earnings

Here's Why We Think SciClone Pharmaceuticals (Holdings) (HKG:6600) Might Deserve Your Attention Today

Dec 14
Here's Why We Think SciClone Pharmaceuticals (Holdings) (HKG:6600) Might Deserve Your Attention Today

Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

Jun 19
Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Upcoming Dividend Will Be Larger Than Last Year's

May 31
SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Upcoming Dividend Will Be Larger Than Last Year's

Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

Feb 17
Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

Calculating The Intrinsic Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

Dec 02
Calculating The Intrinsic Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

We Think You Should Be Aware Of Some Concerning Factors In SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Earnings

Oct 04
We Think You Should Be Aware Of Some Concerning Factors In SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Earnings

SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 25% Dip In Price Shows Sentiment Is Matching Earnings

Jul 27
SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 25% Dip In Price Shows Sentiment Is Matching Earnings

An Intrinsic Calculation For SciClone Pharmaceuticals (Holdings) Limited (HKG:6600) Suggests It's 45% Undervalued

Jun 02
An Intrinsic Calculation For SciClone Pharmaceuticals (Holdings) Limited (HKG:6600) Suggests It's 45% Undervalued

Shareholder Returns

6600HK PharmaceuticalsHK Market
7D0.2%-2.8%-2.3%
1Y69.4%-7.6%-3.6%

Return vs Industry: 6600 exceeded the Hong Kong Pharmaceuticals industry which returned -7.6% over the past year.

Return vs Market: 6600 exceeded the Hong Kong Market which returned -3.6% over the past year.

Price Volatility

Is 6600's price volatile compared to industry and market?
6600 volatility
6600 Average Weekly Movement3.7%
Pharmaceuticals Industry Average Movement5.7%
Market Average Movement7.2%
10% most volatile stocks in HK Market15.2%
10% least volatile stocks in HK Market3.7%

Stable Share Price: 6600's share price has been volatile over the past 3 months.

Volatility Over Time: 6600's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19901,050Hong Zhaowww.sciclone.com

SciClone Pharmaceuticals (Holdings) Limited, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products in the therapeutic areas of oncology and severe infection in Mainland China and internationally. The company’s proprietary product is Zadaxin, which is used for the treatment of chronic hepatitis B. Its in-licensed products include Zometa for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, and hypercalcemia of malignancy; DANYELZA for the treatment of relapsed/refractory high-risk neuroblastoma. The company’s pipeline products comprise Vibativ for the treatment of hospital-acquired and ventilator associated bacterial pneumonia; Omburtamab for the treatment of CNS/leptomeningeal metastasis from neuroblastoma; RRx-001, a small molecule immunotherapeutic, which treats solid tumors; PEN-866, a drug conjugate for solid tumors; HSP90-PI3K SMDC for the treatment of solid tumors; PT-112 for the treatment of late stage prostate cancer and cholangiocarcinoma; and ABTL-0812 for the treatment of endometrial/lung/pancreatic cancer.

SciClone Pharmaceuticals (Holdings) Limited Fundamentals Summary

How do SciClone Pharmaceuticals (Holdings)'s earnings and revenue compare to its market cap?
6600 fundamental statistics
Market capHK$11.26b
Earnings (TTM)HK$1.21b
Revenue (TTM)HK$3.40b

9.4x

P/E Ratio

3.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6600 income statement (TTM)
RevenueCN¥3.16b
Cost of RevenueCN¥799.41m
Gross ProfitCN¥2.36b
Other ExpensesCN¥1.23b
EarningsCN¥1.12b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)1.85
Gross Margin74.67%
Net Profit Margin35.55%
Debt/Equity Ratio0%

How did 6600 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.